Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Selective corneal wavefront-guided transepithelial photorefractive keratectomy on post-corneal graft eyes

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Keratorefractive Surgery Results I

Venue: Poster Village: Pod 2

First Author: : S.Awwad LEBANON

Co Author(s): :    N. El Salloukh   P. Ibrahim                    

Abstract Details

Purpose:

To evaluate the efficacy and safety of selective corneal wavefront guided transepithelial photorefractive keratectomy (CWG TransPRK) on eyes which previously underwent penetrating keratoplasty (PKP) or deep lamellar keratoplasty (DALK) with post-operative irregular astigmatism limiting visual recovery.

Setting:

American University of Beirut Medical Center (AUBMC), Beirut, Lebanon

Methods:

A retrospective chart review of 12 eyes of 12 patients who underwent CWG TransPRK over corneal graft (PKP or DALK) with at least 1 year of post-operative follow up. The aim was to selectively correct higher order aberrations (HOAs) limiting visual acuity in patients intolerant to rigid gas permeable contact lenses (RGPs). All procedures were performed by the same surgeon (STA) using the Schwind Amaris excimer laser with application of 0.02% mitomycin C. Corrected and uncorrected distance visual acuity (CDVA and UDVA), manifest spherical equivalent and cylinder, corneal HOAs and keratometric indices were evaluated pre-operatively and at each visit post-operatively.

Results:

Mean age was 40+/-14.23 years. CDVA LogMAR improved from 0.52+/-0.30 to 0.20+/-0.20 respectively, at 1 years follow up (P<0.0002). Preoperatively and one year postoperatively, corneal total HOAs were 2.09+/-0.70 D, and 1.70+/-0.56 D, Coma was 1.00+/-0.54 D and 0.73+/-0.40 D, Trefoil 1.53+/-0.85 D and 0.98+/-0.68 D, and spherical aberration was 0.79+/-0.43 and 0.72+/-0.44.

Conclusions:

CWG transPRK is an effective procedure to improve the corneal aberrations and visual potential of eyes post corneal graft and intolerant to RGP.

Financial Disclosure:

None

Back to previous